glp 1 agonist with dpp 4 inhibitor Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes GLP-1/GLP-1R: The Star Target for

Participants experiencing adverse reactions or poor effectiveness during the use of weight reduction medications may opt to discontinue the drug

July 11, 2025

Renal function should be monitored in patients with renal impairment or when experiencing severe gastrointestinal adverse effects that could lead to dehydration and acute kidney injury

10.1038/s41392-024-01931-z [DOI] [PMC free article] [PubMed] [Google Scholar] 16.Oprea AD, Umpierrez GE, Sweitzer B, Hepner DL (2024) Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: applying evidence to clinical practice

Pharmacists play a central role in monitoring, counseling on, and facilitating access to GLP-1 RAs, thereby supporting optimal clinical outcomes and therapy tolerability